雷替曲塞为基础化疗方案治疗晚期原发性肝癌的临床观察
发布时间：2019-03-05 19:48
【摘要】：目的回顾性分析雷替曲赛为基础化疗方案治疗晚期原发性肝癌的疗效及安全性。方法 31例原发性肝癌患者,均接受以雷替曲塞为基础方案化疗,其中二线治疗14例,三线及以上治疗17例,方案包括雷替曲塞联合伊立替康(TOMIRI)、雷替曲塞联合奥沙利铂(TOMOX)、雷替曲塞联合吉西他滨(TOMGEM)、雷替曲塞单药(RTX)。按照RECIST1.1版标准评价客观疗效,按照NCICTC 4.0版标准评价不良反应。结果 31例患者完成1周期以上的化疗,均可评价疗效,其中无完全和部分缓解患者,13例患者稳定(SD),18例患者进展(PD),有效率(RR)为0%,疾病控制率(DCR)为41.9%,中位TTP(m TTP)为63天,中位OS(m OS)为189天。常见的不良反应为骨髓抑制及消化道反应,多为Ⅰ~Ⅱ级,患者均可耐受。结论雷替曲塞为基础化疗方案对标准治疗失败的晚期原发性肝癌仍有一定的疾病控制率,且安全性良好,值得进一步深入研究。
[Abstract]:Objective to retrospectively analyze the efficacy and safety of Ritripxil-based chemotherapy in the treatment of advanced primary hepatocellular carcinoma (HCC). Methods Thirty-one patients with primary liver cancer were treated with retitroxil-based chemotherapy, of which 14 patients were treated with second-line therapy and 17 patients were treated with third-line or more. The regimen included Ratetrexil combined with irinotecan (TOMIRI),). Rettrexil combined with oxaliplatin (TOMOX), and gemcitabine (TOMGEM), (RTX). Objective curative effect was evaluated according to RECIST1.1 standard and adverse reaction was evaluated according to NCICTC 4.0 standard. Results 31 patients completed more than one cycle of chemotherapy, and all of them could evaluate the efficacy. There were no complete and partial remission in them. The effective rate of advanced (PD), in 18 patients with stable (SD), was 0%, and the effective rate of (RR) was 0% in 18 patients with stable remission. The disease control rate (DCR) was 41.9%, the median TTP (m TTP) was 63 days and the median OS (m OS) was 189 days. The common adverse reactions were myelosuppression and alimentary tract reactions, most of which were grade 鈪，
本文编号：2435226
[Abstract]:Objective to retrospectively analyze the efficacy and safety of Ritripxil-based chemotherapy in the treatment of advanced primary hepatocellular carcinoma (HCC). Methods Thirty-one patients with primary liver cancer were treated with retitroxil-based chemotherapy, of which 14 patients were treated with second-line therapy and 17 patients were treated with third-line or more. The regimen included Ratetrexil combined with irinotecan (TOMIRI),). Rettrexil combined with oxaliplatin (TOMOX), and gemcitabine (TOMGEM), (RTX). Objective curative effect was evaluated according to RECIST1.1 standard and adverse reaction was evaluated according to NCICTC 4.0 standard. Results 31 patients completed more than one cycle of chemotherapy, and all of them could evaluate the efficacy. There were no complete and partial remission in them. The effective rate of advanced (PD), in 18 patients with stable (SD), was 0%, and the effective rate of (RR) was 0% in 18 patients with stable remission. The disease control rate (DCR) was 41.9%, the median TTP (m TTP) was 63 days and the median OS (m OS) was 189 days. The common adverse reactions were myelosuppression and alimentary tract reactions, most of which were grade 鈪，
本文编号：2435226
本文链接：https://www.wllwen.com/yixuelunwen/zlx/2435226.html
